Skip to content

About Us
Gene Therapies
- Our Approach
- Publications & Presentations
Patients
- Patients & Families
- Patient Spotlights
Pipeline & Programs
- OPGx-BEST1
- OPGx-LCA5
Investors
Contact Us

Publications & Presentations

Scroll to next section

Program

BEST1

LCA5

MERTK

NMNAT1

RDH12

RHO

Location

ARVO

Proceedings of the NASUSA

Proceedings of the NAS

Retinal Degeneration Conference

AOS

CTS

APAO

Macula Society

AEMB

AJOCR

Molecular Therapy

Human Gene Therapy

Cold Spring Harbor Perspectives in Medicine

British Journal of Ophthalmology

Investigative Ophthalmology and Visual Science

Drug Design, Development and Therapy

Nature Genetics

American Journal of Pathology

Molecular Therapy: Methods and Clinical Development

Human Molecular Genetics

AARVO

ASGCT

Retinal Imaging Biomarkers & Endpoints Summit

RD International Symposium

Foundation Fighting Blindness Retinal Therapeutics Innovation Summit

Euretina Congress

Euretina Innovation Summit

Retina Forum

Retina in Rio

LCA5
Retina in Rio
October 2026
Gene Therapy For Congenital Leber Amaurosis (LCA5)
Lead Author: Jorge.
BEST1
Retina in Rio
October 2026
Prediction of Retinal Sensitivity Changes Following Treatment in BEST Disease
Lead Author: Magrath.
BEST1
Retina in Rio
October 2026
Prediction of Retinal Sensitivity Changes Following Treatment in BEST Disease (Video)
Lead Author: Magrath
BEST1
Euretina Congress
October 2026
Initial Results from Cohort 1 of a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations
Lead Author: Pennesi.
Pipeline
Retina Forum
September 2026
Clinical Momentum and Pipeline Progress at Opus Genetics
Lead Author: Tucker.
Pipeline
Euretina Innovation Summit
September 2026
Advancing the Future of IRDs: Opus Genetics Clinical Development Update
Lead Author: Yerxa.
BEST1
Human Gene Therapy
July 2026
Evaluation of the Toxicity and Efficacy of an Adeno-Associated Viral Vector Expressing BEST1 Delivered by Subretinal Injection in a Canine Model of Human Bestrophinopathy
Lead Author: Gray.
BEST1
CTS
June 2026
A Paradigm for Guiding Treatment Decisions in BEST1 AAV Gene Therapy
Lead Author: Jayagopal.
RHO
ARVO
May 2026
Nonclinical Efficacy and Toxicity Study of GMP-Grade Vector OPGx-RHO (Scaav2/5-RHO820-Shrna820) Delivered by Subretinal Injection in a Canine Model of RHO-adRP
Lead Author: Dufour.
LCA5
ARVO
May 2026
Restoration of Cone-Mediated Vision After Gene Augmentation in Children with LCA5
Lead Author: Aleman.
BEST1
ARVO
May 2026
Preliminary Results from Adult Participant in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for ARB and BVMD Due to BEST1 Mutations
Lead Author: Pennesi.
BEST1
ARVO
May 2026
Development of Cell-Based Expression and Functional Potency Assays for OPGx-BEST1 Gene Therapy
Lead Author: Siriwardena.

No publications found.

Sign up to receive our newsletter

Follow us

go to Opus Genetics' Linkedin page go to Opus Genetics' Youtube page

Gene Therapies
Patients & Families
Pipeline & Programs
Publications

About Us
Careers
Contact Us
Investors

© 2026 Opus Genetics, Inc.

Cookie Policy
Privacy Statement

Manage Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options
Manage services
Manage {vendor_count} vendors
Read more about these purposes

View preferences

{title}
{title}
{title}